The US Food and Drug Administration (FDA) last week lifted the clinical hold on Intellia Therapeutics’ investigational new drug (IND) for its nexiguran ziclumeran (nex-z) for amyloidosis. The US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results